Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, the authors provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms.
Scott Buxton
Scott is editor of Physiospot so expect to see his work popping up frequently. Away from the keyboard he is AHP Workforce Development Lead at the Royal United Hospital in Bath as well as an Advanced Practice Physio in Frailty/Geriatrics with a special interest in osteoporosis and sarcopenia.